מדינה: האיחוד האירופי
שפה: אנגלית
מקור: EMA (European Medicines Agency)
carglumic acid
Eurocept International BV
A16AA05
carglumic acid
Other alimentary tract and metabolism products,
Hyperammonemia; Amino Acid Metabolism, Inborn Errors
Ucedane is indicated in treatment of:hyperammonaemia due to N-acetylglutamate synthase primary deficiency;Hyperammonaemia due to isovaleric acidaemia;Hyperammonaemia due to methymalonic acidaemia;Hyperammonaemia due to propionic acidaemia.
Revision: 11
Authorised
2017-06-23
18 B. PACKAGE LEAFLET 19 PACKAGE LEAFLET: INFORMATION FOR THE USER UCEDANE 200 MG DISPERSIBLE TABLETS carglumic acid READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Ucedane is and what it is used for 2. What you need to know before you take Ucedane 3. How to take Ucedane 4. Possible side effects 5. How to store Ucedane 6. Contents of the pack and other information 1. WHAT UCEDANE IS AND WHAT IT IS USED FOR Ucedane can help eliminating excessive ammonia plasma levels (elevated ammonia level in the blood). Ammonia is especially toxic for the brain and leads, in severe cases, to reduced levels of consciousness and to coma. Hyperammonaemia may be due to • the lack of a specific liver enzyme N-acetylglutamate synthase. Patients with this rare disorder are not able to eliminate nitrogen waste, which builds up after eating protein. This disorder persists during the entire life of the affected patient and therefore the need for this treatment is lifelong. • isovaleric acidaemia, methylmalonic acidaemia or propionic acidaemia. Patients suffering from one of these disorders need treatment during the hyperammonaemia crisis. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE UCEDANE DO NOT TAKE UCEDANE if you are allergic to carglumic acid or any of the other ingredients of Ucedane (listed in section 6). Do not take Ucedane during breast-feeding. WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist before taking Ucedane. Ucedane treatment should be initiated under the supervision of a physician experienced קרא את המסמך השלם
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Ucedane 200 mg dispersible tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 200 mg of carglumic acid. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Dispersible tablet. The tablets are rod-shaped, white and biconvex with three score lines on both sides and engraving “L/L/L/L” on one side. Approximate tablet dimensions are 17 mm in length and 6 mm in width. The tablet can be divided into four equal doses. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Ucedane is indicated in treatment of • hyperammonaemia due to N-acetylglutamate synthase primary deficiency. • hyperammonaemia due to isovaleric acidaemia. • hyperammonaemia due to methymalonic acidaemia. • hyperammonaemia due to propionic acidaemia. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Ucedane treatment should be initiated under the supervision of a physician experienced in the treatment of metabolic disorders. Posology • For N-acetylglutamate synthase deficiency: Based on clinical experience, the treatment may be started as early as the first day of life. The initial daily dose should be 100 mg/kg, up to 250 mg/kg if necessary. It should then be adjusted individually in order to maintain normal ammonia plasma levels (see section 4.4). In the long term, it may not be necessary to increase the dose according to body weight as long as adequate metabolic control is achieved; daily doses range from 10 mg/kg to 100 mg/kg. _Carglumic acid responsiveness test _ It is recommended to test individual responsiveness to carglumic acid before initiating any long term treatment. As examples - In a comatose child, start with a dose of 100 to 250 mg/kg/day and measure ammonia plasma concentration at least before each administration. It should normalise within a few hours after starting Ucedane. - In a patient with moderate hyperammonaemia, administer a test dose of 100 to 200 mg/kg/day for 3 days with a constant protein intake and p קרא את המסמך השלם